The Hepatocyte Directed Vesicle (HDV™) Platform
Our active-agnostic HDV™ platform enables peptides, proteins, and hormones to access the portal-hepatic region shifting their activity from peripheral circulation to targeted physiologic action in the portal-hepatic region. By localizing drug activity where key metabolic processes occur, HDV enhances efficacy, safety, and durability.
The platform is safe and effective in both injectable and oral delivery, offering a powerful new approach to metabolic disease treatment.
How HDV™ unlocks new treatments in metabolic therapy
Bicelle Disc Structure
HDV™ is a lipid nanoparticle designed to mimic natural cell membranes, enhancing cellular uptake and bioavailability. Its net negative surface charge enables electrostatic binding with positively charged proteins and peptides.
This structure enhances stability, and utilizes a simple and scalable preparation in both injectable and oral formulations, allowing versatile drug development.
Biotin-PE
Biotin is a naturally occurring coenzyme critical for fatty acid synthesis, glucose metabolism, and gene regulation. In HDV™, Biotin-PE is embedded in the surface membrane, enabling efficient targeting to hepatocytes, where the sodium-dependent multivitamin transporter (SMVT) is most highly expressed, facilitating selective hepatic uptake.
Engineered for Next-Generation Clinical Impact
HDV™ binds up to 100 molecules onto each disc, concentrating and directing biologics and drug therapies through the portal-hepatic highway. This precise localization enables therapies to access the central receptors mediating glucose and lipid metabolism.
Stronger on-target efficacy
Today’s therapies rely on peripheral pharmacology, which results in avoidable side effects. HDV localizes active pharmaceutical ingredients, delivering therapeutic benefit without adding burden to the patient.
Portfolio-wide differentiation
The same HDV architecture adapts to multiple active pharmaceutical ingredients, turning familiar molecules into first-in-class, liver-precise therapies.
De-risked development
Validated pharmacology across three programs and a pristine tox profile create clear regulatory pathways.
Advancing Targeted Therapies to Treat Metabolic Diseases
Pioneering three programs to develop first-in-class therapies for diabetes, obesity, and metabolic disorders.
Insulin
Restoring the liver’s natural role in glucose regulation to prevent hypoglycemia and provide a clinically distinct insulin therapy.
Serotonin
Targeting hepatic serotonin to address the central defect of hepatic and peripheral insulin resistance. Addressing type 2 diabetes and hyperinsulinemia at its root.
Incretins (GLP-1)
Localizing GLP-1 activity in the portal vein to access the gut-liver-brain-axis, providing patients a healthier more durable therapy for weight loss, glucose and fat control.
Targeting the portal-hepatic region—where metabolic regulation begins—offers a new path forward for restoring glucose and lipid balance in diabetes, obesity, and related diseases.
Curious about where we are in development?
Our research pipeline is dedicated to advancing HDV™ technology into new frontiers of metabolic medicine.
.avif)